

Australia

Patents Act 1990

NOTICE OF ENTITLEMENT

I, John Gordon Hinde, of Spruson & Ferguson, St Martins Tower, 31 Market Street, Sydney, New South Wales 2000, Australia, being the patent attorney for the Applicant(s)/Nominated Person(s) in respect of Application No 34353/93 state the following:-

The Applicant(s)/Nominated Person(s) has/have entitlement from the actual inventor(s) as follows:-

The Applicant(s)/Nominated Person(s) is/are the assignee(s) of the actual inventor(s).

The Applicant(s)/Nominated Person(s) is/are entitled to rely on the application(s) listed in the Declaration under Article 8 of the PCT as follows:

The Applicant(s)/Nominated Person(s) is/are the assignee(s) of the basic applicant(s).

The basic application(s) listed on the Declaration under Article 8 of the PCT is/are the first application(s) made in a Convention country in respect of the invention.

DATED this 28th day of July 19 94

.....
John Gordon Hinde

IRN: 276903

INSTR CODE: 53100

5



AU9334353

(12) PATENT ABRIDGMENT (11) Document No. AU-B-34353/93
(19) AUSTRALIAN PATENT OFFICE (10) Acceptance No. 680609

- (54) Title
MAREK'S DISEASE VIRUS RECOMBINANT POXVIRUS VACCINE
- International Patent Classification(s)
(51)⁵ C12N 015/39 C12N 007/01 C12P 019/34 C12P 021/02
A61K 039/255
(51)⁶ A61K 035/76
- (21) Application No. : 34353/93 (22) Application Date : 07.01.93
- (87) PCT Publication Number : WO93/14219
- (30) Priority Data
- | (31) Number | (32) Date | (33) Country |
|-------------|-----------|-----------------------------|
| 820077 | 13.01.92 | US UNITED STATES OF AMERICA |
| 001391 | 06.01.93 | US UNITED STATES OF AMERICA |
- (43) Publication Date : 03.08.93
- (44) Publication Date of Accepted Application : 07.08.97
- (71) Applicant(s)
VIROGENETICS CORPORATION
- (72) Inventor(s)
ENZO PAOLETTI; JILL TAYLOR; JAMES TARTAGLIA; LOUIS ROSS
- (74) Attorney or Agent
SPRUSON & FERGUSON, GPO Box 3898, SYDNEY NSW 2001

- (57) Cell Lines and Virus Strains. The strain of FPV designated FP-1 has been previously described (Taylor et al., 1988a,b). It is an attenuated vaccine strain useful in vaccination of day old chickens. The parental virus, Duvette strain, was obtained from Rhone Merieux, Lyon, France. The virus received by Virogenetics was subjected to four successive plaque purifications. One plaque isolate was further amplified in primary CEF cells, and a stock virus, designated as TROVAC, established.

CLAIM

1. A recombinant poxvirus, containing therein DNA from Marek's disease virus coding for Marek's disease virus glycoprotein gB or gD in a nonessential region of the poxvirus genome, wherein said poxvirus is selected from the group consisting of:

(i) a recombinant vaccinia virus wherein regions C7L-K1L, J2R, B13R+B14R, A56R, and IL4 have been deleted therefrom, and further comprising exogenous DNA from Marek's disease virus coding for Marek's disease virus glycoprotein gB or gD in a nonessential region of the vaccinia genome;

(ii) a recombinant vaccinia virus wherein the open reading frames for the thymidine kinase gene, the hemorrhagic region, the A type inclusion body region, the hemagglutinin gene, the host range region, and the large subunit, ribonucleotide reductase

(11) AU-B-34353/93
(10) 680609

-2-

have been deleted therefrom, and further comprising exogenous DNA from Marek's disease virus coding for Marek's disease virus glycoprotein gB or gD in a nonessential region of the vaccinia genome; and

(iii) a recombinant poxvirus having virus encoded genetic functions inactivated therein so that the virus has attenuated virulence; said poxvirus further comprising exogenous DNA from Marek's disease virus coding for Marek's disease virus glycoprotein gB or gD and is inserted by recombination in a nonessential region of the poxvirus genome; wherein said poxvirus is a fowlpox virus which as attenuated virulence through approximately 50 serial passages in chicken embryonated eggs followed by 25 passages on chicken embryo fibroblast cells, then subjecting the virus to four successive plaque purifications, and obtaining a plaque isolate and further amplifying the isolate in primary chick embryo fibroblast cells.

10. A recombinant poxvirus comprising exogenous DNA from Marek's disease virus coding for Marek's disease virus glycoprotein gB or gD which is inserted by recombination in a nonessential region of the poxvirus genome; wherein said poxvirus is a TROVAC recombinant fowlpox.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12P 21/02, 19/34, C12N 15/00 C12N 7/00, 5/00, A61K 39/12 C07K 3/00	A1	(11) International Publication Number: WO 93/14219 (43) International Publication Date: 22 July 1993 (22.07.93)
(21) International Application Number: PCT/US93/00084 (22) International Filing Date: 7 January 1993 (07.01.93) (30) Priority data: 820,077 13 January 1992 (13.01.92) US 001,391 6 January 1993 (06.01.93) US (71) Applicant: VIROGENETICS CORPORATION [US/US]; 465 Jordan Road, Rensselaer Technology Park, Troy, NY 12180 (US). (72) Inventors: PAOLETTI, Enzo ; 297 Murray Avenue, Del- mar, NY 12054 (US). TAYLOR, Jill ; 33 Colonial Ave- nue, Albany, NY 12203-2011 (US). TARTAGLIA, James ; 7 Christina Drive, Schenectady, NY 12303 (US). ROSS, Louis ; Spinney House, Rust Lane, Alconbury, Hunting- don PE17 5DN (GB).		(74) Agents: FROMMER, William, S. et al.; Curtis, Morris & Safford, 530 Fifth Avenue, New York, NY 10036 (US). (81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> 680609
(54) Title: MAREK'S DISEASE VIRUS RECOMBINANT POXVIRUS VACCINE (57) Abstract What is described is a recombinant poxvirus, such as vaccinia virus or fowlpox virus, containing foreign DNA from Marek's disease virus. What is also described is a vaccine containing the recombinant poxvirus for inducing an immunological response in a host animal inoculated with the vaccine.		

MAREK'S DISEASE VIRUS RECOMBINANT POXVIRUS VACCINE

FIELD OF THE INVENTION

The present invention relates to a modified poxvirus and to methods of making and using the same.

5 More in particular, the invention relates to recombinant poxvirus, which virus expresses gene products of a Marek's disease virus (MDV) gene, and to vaccines which provide protective immunity against MDV infections.

Several publications are referenced in this
10 application. Full citation to these references is found at the end of the specification immediately preceding the claims. These references describe the state-of-the-art to which this invention pertains.

BACKGROUND OF THE INVENTION

15 Vaccinia virus and more recently other poxviruses have been used for the insertion and expression of foreign genes. The basic technique of inserting foreign genes into live infectious poxvirus involves recombination between pox DNA sequences flanking
20 a foreign genetic element in a donor plasmid and homologous sequences present in the rescuing poxvirus (Piccini et al., 1987).

Specifically, the recombinant poxviruses are constructed in two steps known in the art and analogous
25 to the methods for creating synthetic recombinants of the vaccinia virus described in U.S. Patent No. 4,603,112, the disclosure of which patent is incorporated herein by reference.

First, the DNA gene sequence to be inserted
30 into the virus, particularly an open reading frame from a non-pox source, is placed into an *E. coli* plasmid construct into which DNA homologous to a section of DNA of the poxvirus has been inserted. Separately, the DNA gene sequence to be inserted is ligated to a promoter.
35 The promoter-gene linkage is positioned in the plasmid construct so that the promoter-gene linkage is flanked on both ends by DNA homologous to a DNA sequence flanking a

region of pox DNA containing a nonessential locus. The resulting plasmid construct is then amplified by growth within *E. coli* bacteria (Clewell, 1972) and isolated (Clewell et al., 1969; Maniatis et al., 1982).

5 Second, the isolated plasmid containing the DNA gene sequence to be inserted is transfected into a cell culture, e.g. chick embryo fibroblasts, along with the poxvirus. Recombination between homologous pox DNA in the plasmid and the viral genome respectively gives a
10 poxvirus modified by the presence, in a nonessential region of its genome, of foreign DNA sequences. The term "foreign" DNA designates exogenous DNA, particularly DNA from a non-pox source, that codes for gene products not ordinarily produced by the genome into which the
15 exogenous DNA is placed.

Genetic recombination is in general the exchange of homologous sections of DNA between two strands of DNA. In certain viruses RNA may replace DNA. Homologous sections of nucleic acid are sections of
20 nucleic acid (DNA or RNA) which have the same sequence of nucleotide bases.

Genetic recombination may take place naturally during the replication or manufacture of new viral genomes within the infected host cell. Thus, genetic
25 recombination between viral genes may occur during the viral replication cycle that takes place in a host cell which is co-infected with two or more different viruses or other genetic constructs. A section of DNA from a first genome is used interchangeably in constructing the
30 section of the genome of a second co-infecting virus in which the DNA is homologous with that of the first viral genome.

However, recombination can also take place between sections of DNA in different genomes that are not
35 perfectly homologous. If one such section is from a first genome homologous with a section of another genome except for the presence within the first section of, for

example, a genetic marker or a gene coding for an antigenic determinant inserted into a portion of the homologous DNA, recombination can still take place and the products of that recombination are then detectable by the presence of that genetic marker or gene in the recombinant viral genome.

Successful expression of the inserted DNA genetic sequence by the modified infectious virus requires two conditions. First, the insertion must be into a nonessential region of the virus in order that the modified virus remain viable. The second condition for expression of inserted DNA is the presence of a promoter in the proper relationship to the inserted DNA. The promoter must be placed so that it is located upstream from the DNA sequence to be expressed.

An attenuated vector has been developed by the sequential deletion of six non-essential regions from the Copenhagen strain of vaccinia virus. These regions are known to encode proteins that may have a role in viral virulence. The regions deleted are the tk gene, the hemorrhagic gene, the A-type inclusion gene, the hemagglutinin gene and the gene encoding the large subunit of the ribonucleotide reductase as well as the C7L through K1L sequences defined previously (Perkus et al., 1990). The sequences and genomic locations of these genes in the Copenhagen strain of vaccinia virus have been defined previously (Goebel et al., 1990a,b). The resulting attenuated vaccinia strain is designated as NYVAC.

The technology of generating vaccinia virus recombinants has recently been extended to other members of the poxvirus family which have a more restricted host range.

Fowlpox virus (FPV) has advantageously been engineered as a vector expressing antigens from poultry pathogens. The hemagglutinin protein of a virulent avian influenza virus was expressed in an FPV recombinant

(Taylor et al., 1988a). After inoculation of the recombinant into chickens and turkeys, an immune response was induced which was protective against either a homologous or heterologous virulent influenza virus challenge (Taylor et al., 1988a). In addition, the surface glycoproteins (fusion and hemagglutinin) of a virulent strain of Newcastle Disease Virus have been expressed in an FPV vector and shown to induce a protective immune response (Taylor et al., 1990; Edbauer et al., 1990, Boursnell et al., 1990a,b).

FPV is the prototypic virus of the Avipox genus of the Poxvirus family. The virus causes an economically important disease of poultry which has been well controlled since the 1920's by the use of live attenuated vaccines. Replication of the avipox viruses is limited to avian species (Esposito, 1991) and there are no reports in the literature of the virus causing a productive infection in any non-avian species including man. This host restriction provides an inherent safety barrier to transmission of the virus to other species and makes use of FPV as a vaccine vector in poultry an attractive proposition.

Marek's Disease is a lymphoproliferative disease of chickens caused by infection with the herpes virus MDV. The disease is characterized by a mononuclear infiltration of one or more of the following areas; peripheral nerves, gonad, iris, various viscera, muscles and skin (Calnek and Witter, 1991). There are three serotypes of relevance; (1) Serotype 1 which contains oncogenic MDVs (2) Serotype 2 which contains non-oncogenic MDVs and (3) Serotype 3 which contains the closely related herpes virus of turkeys (HVT).

The biology of MDV has been reviewed by Schat (1987). The mode of infection of MDV is via direct or indirect contact between birds, allowing virus spread by the airborne route. After initial contact, three phases of viral infection are apparent. The first phase is

defined as an early cytolytic infection. During this phase, productive infection resulting in the release of cell-free virus will occur in the feather follicle epithelium (FFE). At the same time, a non-productive replication occurs in the lymphoid organs. Defined as a productive-restrictive infection, during this stage, DNA replication occurs and MDV antigens are expressed but the virions produced are non-enveloped and thus non-infectious (Calnek and Witter, 1991). The productive restrictive infection results in the necrosis of B-lymphocytes accompanied by infiltration of macrophages and granulocytes and hyperplasia of reticular cells leading to splenic enlargement (Payne et al., 1976). As a result T cells become activated and express MHC class II (Ia) antigens (Schat, 1987). Activated T cells, but not resting T cells, then become susceptible to infection with MDV (Calnek et al., 1984, 1985). The transient immunosuppression which is associated with early cytolytic infection is probably due, therefore, to lytic infection of B cells in the spleen and bursa (Schat, 1987).

Following this phase, infected birds enter the second stage defined as latent infection. The infected T cells, in which the viral genome is present, do not produce viral antigens nor viral particles. Latent infections are established approximately six days after initial infection of the bird.

The third and final phase is characterized by a secondary cytolytic infection, immunosuppression and tumor formation. This type of infection occurs only with virulent serotype 1 viruses. A secondary cytolytic infection occurs in the FFE and this is the only area where infectious cell-free virus is produced. The importance of this inflammatory infection in tumor formation is not clear, however it is thought that latently infected lymphocytes are attracted to the FFE where they undergo blastogenesis. This may be a

requirement for their transformation into tumor cells. In addition, uninfected lymphocytes are attracted to the sites of infection where they become cytolytically infected or transform to tumor cells (Schat, 1987).

- 5 Permanent immunosuppression is often evident at this time. The change from a latent infection is also characterized by tumor formation in visceral organs, nerves, muscles and skin (Payne et al., 1976, Payne, 1985) and the tumor cells now express a number of MDV
10 antigens.

Prior to the use of vaccines, MDV constituted an economically important disease to the poultry industry. Current vaccines are of three types (1) highly attenuated serotype 1 viruses, (2) naturally avirulent
15 serotype 2 viruses, or (3) the serologically related HVT viruses. The most effective and most extensively used are the HVT vaccines developed by Okazaki et al. (1970). Problems do exist in current vaccination strategies caused by improper handling of the vaccine, interference
20 by maternal antibody and associated stress and concurrent infections. In addition, the emergence of highly virulent MDV strains against which immunization with HVT alone is not protective has led to the inclusion of multiple serotypes in vaccines (reviewed by Calnek and
25 Witter, 1991).

The MDV isolates have been classified as gamma herpes viruses on the basis of their predilection for lymphocytes. However, in recent years, considerable effort has been spent on understanding the genomic
30 organization of MDV and it is now apparent that there is more genetic homology with alpha herpes viruses than with gamma herpes viruses (Ross et al., 1989, 1991). Using this approach, a number of antigens important in eliciting an immune response have been identified. Among
35 these antigens are the HSV1 gB homolog and HSV gD homolog. The HSV1 gB homolog was identified by Ross et al. (1989). In other herpes virus diseases the gB

glycoprotein has been shown to induce both humoral and cell-mediated immune responses and to confer protective immunity (Cantin et al., 1987, Marchioli et al., 1987, Guo et al., 1990). In MDV infected cells the B antigen is a complex of glycoproteins with molecular weights of 100 kD, 60 kD and 49 kD (Calnek and Witter, 1991). The antigen is located on the infected cell surface and in the cytoplasm (Kato and Hirai, 1935) and is thought to induce neutralizing antibodies (Ono et al., 1985).

Similarly, the MDV homolog of the HSV-1 gD was identified by Ross and Binns (1991) and Ross et al. (1991). The HSV gD has been shown to be an effective immunogen against HSV infection (Paoletti et al., 1984, Cremer et al., 1985).

Although current vaccination strategies against MDV have been quite successful, the emergence of highly virulent MDV strains which are not adequately controlled by current HVT vaccines indicates that inclusion of multiple immunogens of highly virulent strains in a vaccine may provide for a broader immune response.

It can thus be appreciated that provision of a MDV recombinant poxvirus, and of a recombinant based vaccine which provides protective immunity against MDV infections and in which multiple immunogens of MDV could be expressed, would be a highly desirable advance over the current state of technology.

OBJECTS OF THE INVENTION

It is therefore an object of this invention to provide recombinant poxviruses, which viruses express gene products of MDV, and to provide a method of making such recombinant poxviruses.

It is an additional object of this invention to provide for the cloning and expression of MDV coding sequences, particularly sequences coding for antigenically relevant glycoproteins from MDV, in a poxvirus vector, particularly vaccinia virus or fowlpox virus vectors.

It is another object of this invention to provide a vaccine which is capable of eliciting MDV neutralizing antibodies and protective immunity against MDV infection.

These and other objects and advantages of the present invention will become more readily apparent after consideration of the following.

Statement of the Invention

According to the first embodiment of the invention there is provided a recombinant poxvirus, containing therein DNA from Marek's disease virus coding for Marek's disease virus glycoprotein gB or gD in a nonessential region of the poxvirus genome, wherein said poxvirus is selected from the group consisting of:

(i) a recombinant vaccinia virus wherein regions C7L-K1L, J2R, B13R+B14R, A56R, and IL4 have been deleted therefrom, and further comprising exogenous DNA from Marek's disease virus coding for Marek's disease virus glycoprotein gB or gD in a nonessential region of the vaccinia genome;

(ii) a recombinant vaccinia virus wherein the open reading frames for the thymidine kinase gene, the hemorrhagic region, the A type inclusion body region, the hemagglutinin gene, the host range region, and the large subunit, ribonucleotide reductase have been deleted therefrom, and further comprising exogenous DNA from Marek's disease virus coding for Marek's disease virus glycoprotein gB or gD in a nonessential region of the vaccinia genome; and

(iii) a recombinant poxvirus having virus encoded genetic functions inactivated therein so that the virus has attenuated virulence; said poxvirus further comprising exogenous DNA from Marek's disease virus coding for Marek's disease virus glycoprotein gB or gD and is inserted by recombination in a nonessential region of the poxvirus genome; wherein said poxvirus is a fowlpox virus which as attenuated virulence through approximately 50 serial passages in chicken embryonated eggs followed by 25 passages on chicken embryo fibroblast cells, then subjecting the virus to four successive plaque purifications, and obtaining a plaque isolate and further amplifying the isolate in primary chick embryo fibroblast cells.

According to the present invention, the recombinant poxvirus expresses gene products of the foreign MDV gene. In particular, the foreign DNA codes for a structural protein, especially an antigenically relevant glycoprotein, from MDV. Advantageously, a plurality of MDV glycoproteins are co-expressed in the host by the recombinant poxvirus.

In another aspect, the present invention relates to a vaccine for inducing an immunological response in a host animal inoculated with the vaccine, said vaccine including a carrier and a recombinant poxvirus in accordance with the first embodiment of the invention. Advantageously, the DNA codes for and expresses a MDV structural protein, particularly a MDV glycoprotein. A plurality of MDV glycoproteins advantageously are co-expressed in the host. The poxvirus used in the vaccine according



to the present invention is advantageously a vaccinia virus or an avipox virus, such as fowlpox virus.

According to a further aspect of the invention there is provided a recombinant vaccinia virus in accordance with the first embodiment of the invention wherein regions
5 C7L-K1L, J2R, B13R+B14R, A56R, and I4L have been deleted therefrom, and further comprising exogenous DNA from Marek's disease virus coding for a Marek's disease virus glycoprotein in a nonessential region of the vaccinia genome.

According to a further aspect of the invention there is provided a recombinant vaccinia virus in accordance with the first embodiment of the invention wherein the open
10 reading frames for the thymidine kinase gene, the hemorrhagic region, the A type inclusion body region, the hemagglutinin gene, the host range region, and the large subunit, ribonucleotide reductase have been deleted therefrom, and further comprising exogenous DNA from Marek's disease virus coding for a Marek's disease virus glycoprotein in a nonessential region of the vaccinia genome.

15 According to a further aspect of the invention there is provided a poxvirus in accordance with the first embodiment of the invention having virus encoded genetic functions inactivated therein so that the virus has attenuated virulence; said poxvirus further comprising exogenous DNA from Marek's disease virus coding for a Marek's disease virus glycoprotein and is inserted by recombination in a nonessential region of the
20 poxvirus genome; wherein said poxvirus is a fowlpox virus which as attenuated virulence through approximately 50 serial passages in chicken embryonated eggs followed by 25 passages on chicken embryo fibroblast cells, then subjecting the virus to four successive plaque purifications, and obtaining a plaque isolate and further amplifying the isolate in primary chick embryo fibroblast cells.

25 According to a further aspect of the invention there is provided a recombinant poxvirus in accordance with the first embodiment of the invention, wherein the poxvirus contains exogenous DNA for a promoter linked to the DNA from Marek's disease virus.

According to a further aspect of the invention there is provided an immunological composition for inducing an immunological response in a chicken inoculated with said
30 composition, said comprising a carrier and a recombinant poxvirus, selected from the group consisting of vaccinia virus and avipox virus, containing therein DNA from Marek's disease virus coding for a Marek's disease virus glycoprotein in a nonessential region of the poxvirus genome.

According to a further aspect of the invention there is provided a recombinant
35 poxvirus comprising exogenous DNA from Marek's disease virus coding for a Marek's disease virus glycoprotein which is inserted by recombination in a nonessential region of the poxvirus genome; wherein said poxvirus is a TROVAC recombinant fowlpox.



BRIEF DESCRIPTION OF THE DRAWINGS

A better understanding of the present invention will be had by referring to the accompanying drawings, in which:

5 FIG. 1 schematically shows a method for the construction of plasmid pSD460 for deletion of thymidine kinase gene and generation of recombinant vaccinia virus VP410;

10 FIG. 2 schematically shows a method for the construction of plasmid pSD486 for deletion of hemorrhagic region and generation of recombinant vaccinia virus VP553;

15 FIG. 3 schematically shows a method for the construction of plasmid pMP494A for deletion of ATI region and generation of recombinant vaccinia virus VP618;

20 FIG. 4 schematically shows a method for the construction of plasmid pSD467 for deletion of hemagglutinin gene and generation of recombinant vaccinia virus VP723;

 FIG. 5 schematically shows a method for the construction of plasmid pMPCSK1A for deletion of gene cluster [C7L - K1L] and generation of recombinant vaccinia virus VP804;

25 FIG. 6 schematically shows a method for the construction of plasmid pSD548 for deletion of large subunit, ribonucleotide reductase and generation of recombinant vaccinia virus VP866 (NYVAC); and

30 FIG. 7 is a plot of mortality of chickens over time for control groups (challenged by inoculation or by contact) and a vaccinated group (vaccinated with vFP108 and challenged by contact).

DETAILED DESCRIPTION OF THE INVENTION

35 The invention is directed to recombinant poxviruses containing therein a DNA sequence from MDV in a nonessential region of the poxvirus genome. The recombinant poxviruses express gene products of the

foreign MDV gene. In particular, MDV genes encoding MDV structural proteins were isolated, characterized and inserted into NYVAC (vaccinia virus) and TROVAC (fowlpox virus) recombinants.

5 Cell Lines and Virus Strains. The strain of FPV designated FP-1 has been previously described (Taylor et al., 1988a,b). It is an attenuated vaccine strain useful in vaccination of day old chickens. The parental virus, Duvette strain, was obtained from Rhone Merieux,
10 Lyon, France. The virus received by Virogenetics was subjected to four successive plaque purifications. One plaque isolate was further amplified in primary CEF cells, and a stock virus, designated as TROVAC, established.

15 All recombination tests, plaque assays and amplifications with TROVAC or TROVAC based recombinants were performed in primary CEF monolayers made from 10-11 day old embryonated eggs of SPF origin.

 The vaccinia virus strain used as a rescue for
20 MDV sequences was NYVAC (vP866). NYVAC is a highly attenuated strain of vaccinia virus derived from the Copenhagen strain by deletion of 18 open reading frames which have been implicated in determining viral virulence and host range restriction. Recombinant plaque selection
25 and virus amplifications were performed on rabbit kidney cells (RK13, ATCC CCL37).

 Plasmids pMDV517 and pUC13gB contain DNA sequences encoding MDV gD and gB glycoproteins from strain RB1B. Plasmid pUC13gB contains a 3.9 Kb DNA
30 fragment of genomic DNA of MDV (strain RB1B). The fragment which contains the MDVgB gene is inserted into pUC13 as an EcoRI-SalI fragment. The sequence of the inserted fragment is described in Ross et al. (1989). Plasmid pMDV517 contains a 5.2 Kb DNA fragment of genomic
35 DNA of MDV (strain RB1B). The fragment which contains the MDVgD gene is inserted at the EcoRI site of pUC13.

The sequence of the fragment is described in Ross et al. (1991).

Example 1 - ATTENUATED VACCINIA VACCINE STRAIN NYVAC

To develop a new vaccinia vaccine strain, the
5 Copenhagen vaccine strain of vaccinia virus was modified
by the deletion of six nonessential regions of the genome
encoding known or potential virulence factors. The
sequential deletions are detailed below. All
designations of vaccinia restriction fragments, open
10 reading frames and nucleotide positions are based on the
terminology reported in Goebel et al. (1990a,b).

The deletion loci were also engineered as
recipient loci for the insertion of foreign genes.

The regions sequentially deleted in NYVAC are
15 listed below. Also listed are the abbreviations and open
reading frame designations for the deleted regions
(Goebel et al., 1990a,b) and the designation of the
vaccinia recombinant (vP) containing all deletions
through the deletion specified:

- 20 (1) thymidine kinase gene (TK; J2R) vP410;
- (2) hemorrhagic region (H; B13R + B14R) vP553;
- (3) A type inclusion body region (ATI; A26L) vP618;
- (4) hemagglutinin gene (HA; A56R) vP723;
- (5) host range gene region (C7L - K1L) vP804; and
- 25 (6) large subunit, ribonucleotide reductase (I4L)
vP866 (NYVAC).

DNA Cloning and Synthesis. Plasmids were
constructed, screened and grown by standard procedures
(Maniatis et al., 1982; Perkus et al., 1985; Piccini et
30 al., 1987). Restriction endonucleases were obtained from
GIBCO/BRL, Gaithersburg, MD; New England Biolabs,
Beverly, MA; and Boehringer Mannheim Biochemicals,
Indianapolis, IN. Klenow fragment of *E. coli* polymerase
was obtained from Boehringer Mannheim Biochemicals. BAL-
35 31 exonuclease and phage T4 DNA ligase were obtained from
New England Biolabs. The reagents were used as specified
by the various suppliers.

Synthetic oligodeoxyribonucleotides were prepared on a Biosearch 8750 or Applied Biosystems 380B DNA synthesizer as previously described (Perkus et al., 1989). DNA sequencing was performed by the dideoxy-chain termination method (Sanger et al., 1977) using Sequenase (Tabor et al., 1987) as previously described (Guo et al., 1989). DNA amplification by polymerase chain reaction (PCR) for sequence verification (Engelke et al., 1988) was performed using custom synthesized oligonucleotide primers and GeneAmp DNA amplification Reagent Kit (Perkin Elmer Cetus, Norwalk, CT) in an automated Perkin Elmer Cetus DNA Thermal Cycler. Excess DNA sequences were deleted from plasmids by restriction endonuclease digestion followed by limited digestion by BAL-31 exonuclease and mutagenesis (Mandecki, 1986) using synthetic oligonucleotides.

Cells, Virus, and Transfection. The origins and conditions of cultivation of the Copenhagen strain of vaccinia virus has been previously described (Guo et al., 1989). Generation of recombinant virus by recombination, *in situ* hybridization of nitrocellulose filters and screening for B-galactosidase activity are as previously described (Panicali et al., 1982; Perkus et al., 1989).

Construction of Plasmid pSD460 for Deletion of Thymidine Kinase Gene (J2R). Referring now to FIG. 1, plasmid pSD406 contains vaccinia HindIII J (pos. 83359 - 88377) cloned into pUC8. pSD406 was cut with HindIII and PvuII, and the 1.7 kb fragment from the left side of HindIII J cloned into pUC8 cut with HindIII/SmaI, forming pSD447. pSD447 contains the entire gene for J2R (pos. 83855 - 84385). The initiation codon is contained within an NlaIII site and the termination codon is contained within an SspI site. Direction of transcription is indicated by an arrow in FIG. 1.

To obtain a left flanking arm, a 0.8 kb HindIII/EcoRI fragment was isolated from pSD447, then digested with NlaIII and a 0.5 kb HindIII/NlaIII fragment

isolated. Annealed synthetic oligonucleotides
MPSYN43/MPSYN44 (SEQ ID NO:1/SEQ ID NO:2)

SmaI

MPSYN43 5' TAATTAAGCTACCCGGG 3'

5 MPSYN44 3' GTACATTAATTGATCGATGGGCCCTTAA 5'

NlaIII EcoRI

were ligated with the 0.5 kb HindIII/NlaIII fragment into
pUC18 vector plasmid cut with HindIII/EcoRI, generating
10 plasmid pSD449.

To obtain a restriction fragment containing a
vaccinia right flanking arm and pUC vector sequences,
pSD447 was cut with SspI (partial) within vaccinia
sequences and HindIII at the pUC/vaccinia junction, and a
15 2.9 kb vector fragment isolated. This vector fragment
was ligated with annealed synthetic oligonucleotides
MPSYN45/MPSYN46 (SEQ ID NO:3/SEQ ID NO:4)

HindIII SmaI

MPSYN45 5' AGCTTCCCGGGTAAGTAATACGTCAAGGAGAAAACGAA

20 MPSYN46 3' AGGGCCCATTCATTATGCAGTTCCTCTTTTGCTT

NotI SspI

ACGATCTGTAGTTAGCGGCCGCTAATTAATAAT 3'

MPSYN45

25 TGCTAGACATCAATCGCCGGCGGATTAATTGATTA 5'

MPSYN46

generating pSD459.

To combine the left and right flanking arms
30 into one plasmid, a 0.5 kb HindIII/SmaI fragment was
isolated from pSD449 and ligated with pSD459 vector
plasmid cut with HindIII/SmaI, generating plasmid pSD460.
pSD460 was used as donor plasmid for recombination with
wild type parental vaccinia virus Copenhagen strain VC-2.
35 A ³²P labelled probe was synthesized by primer extension
using MPSYN45 (SEQ ID NO:3) as template and the
complementary 20mer oligonucleotide MPSYN47 (SEQ ID NO:5)
(5' TTAGTTAATTAGGCGGCCGC 3') as primer. Recombinant virus
vP410 was identified by plaque hybridization.

40 Construction of Plasmid pSD486 for Deletion of
Hemorrhagic Region (B13R + B14R). Referring now to FIG.
2, plasmid pSD419 contains vaccinia SalI G (pos. 160,744-

173,351) cloned into pUC8. pSD422 contains the contiguous vaccinia SalI fragment to the right, SalI J (pos. 173,351-182,746) cloned into pUC8. To construct a plasmid deleted for the hemorrhagic region, u, B13R -
5 B14R (pos. 172,549 - 173,552), pSD419 was used as the source for the left flanking arm and pSD422 was used as the source of the right flanking arm. The direction of transcription for the u region is indicated by an arrow in FIG. 2.

10 To remove unwanted sequences from pSD419, sequences to the left of the NcoI site (pos. 172,253) were removed by digestion of pSD419 with NcoI/SmaI followed by blunt ending with Klenow fragment of *E. coli* polymerase and ligation generating plasmid pSD476. A
15 vaccinia right flanking arm was obtained by digestion of pSD422 with HpaI at the termination codon of B14R and by digestion with NruI 0.3 kb to the right. This 0.3 kb fragment was isolated and ligated with a 3.4 kb HincII vector fragment isolated from pSD476, generating plasmid
20 pSD477. The location of the partial deletion of the vaccinia u region in pSD477 is indicated by a triangle. The remaining B13R coding sequences in pSD477 were removed by digestion with ClaI/HpaI, and the resulting vector fragment was ligated with annealed synthetic
25 oligonucleotides SD22mer/SD20mer (SEQ ID NO:6/SEQ ID NO:7)

ClaI BamHI HpaI
SD22mer 5' CGATTACTATGAAGGATCCGTT 3'
SD20mer 3' TAATGATACTTCCTAGGCAA 5'

30

generating pSD479. pSD479 contains an initiation codon (underlined) followed by a BamHI site. To place *E. coli* Beta-galactosidase in the B13-B14 (u) deletion locus
35 under the control of the u promoter, a 3.2 kb BamHI fragment containing the Beta-galactosidase gene (Shapira et al., 1983) was inserted into the BamHI site of pSD479, generating pSD479BG. pSD479BG was used as donor plasmid for recombination with vaccinia virus vP410. Recombinant

vaccinia virus VP533 was isolated as a blue plaque in the presence of chromogenic substrate X-gal. In VP533 the B13R-B14R region is deleted and is replaced by Beta-galactosidase.

5 To remove Beta-galactosidase sequences from VP533, plasmid pSD486, a derivative of pSD477 containing a polylinker region but no initiation codon at the u deletion junction, was utilized. First the ClaI/HpaI vector fragment from pSD477 referred to above was ligated
10 with annealed synthetic oligonucleotides SD42mer/SD40mer (SEQ ID NO:8/SEQ ID NO:9)

	<u>ClaI</u>	<u>SacI</u>	<u>XhoI</u>	<u>HpaI</u>
	SD42mer 5' CGATTACTAGATCTGAGCTCCCCGGGCTCGAGGGATCCGTT 3'			
	SD40mer 3' TAATGATCTAGACTCGAGGGGCCGAGCTCCCTAGGCAA 5'			
15	<u>BglII</u>	<u>SmaI</u>	<u>BamHI</u>	

generating plasmid pSD478. Next the EcoRI site at the pUC/vaccinia junction was destroyed by digestion of pSD478 with EcoRI followed by blunt ending with Klenow
20 fragment of *E. coli* polymerase and ligation, generating plasmid pSD478E⁻. pSD478E⁻ was digested with BamHI and HpaI and ligated with annealed synthetic oligonucleotides HEM5/HEM6 (SEQ ID NO:10/SEQ ID NO:11)

	<u>BamHI</u>	<u>EcoRI</u>	<u>HpaI</u>
25	HEM5 5' GATCCGAATTCTAGCT 3'		
	HEM6 3' GCTTAAGATCGA 5'		

generating plasmid pSD486. pSD486 was used as donor plasmid for recombination with recombinant vaccinia virus
30 VP533, generating VP553, which was isolated as a clear plaque in the presence of X-gal.

Construction of Plasmid pMP494A for Deletion of ATI Region (A26L). Referring now to FIG. 3, pSD414 contains SalI B cloned into pUC8. To remove unwanted DNA
35 sequences to the left of the A26L region, pSD414 was cut with XbaI within vaccinia sequences (pos. 137,079) and with HindIII at the pUC/vaccinia junction, then blunt ended with Klenow fragment of *E. coli* polymerase and ligated, resulting in plasmid pSD483. To remove unwanted
40 vaccinia DNA sequences to the right of the A26L region,

pSD483 was cut with EcoRI (pos. 140,665 and at the pUC/vaccinia junction) and ligated, forming plasmid pSD484. To remove the A26L coding region, pSD484 was cut with NdeI (partial) slightly upstream from the A26L ORF
 5 (pos. 139,004) and with HpaI (pos. 137,889) slightly downstream from the A26L ORF. The 5.2 kb vector fragment was isolated and ligated with annealed synthetic oligonucleotides ATI3/ATI4 (SEQ ID NO:12/SEQ ID NO:13)

NdeI

10 ATI3 5' TATGAGTAACTTAACTCTTTTGTTAATTAAAAGTATAATTCAAAAAATAAGT
 ATI4 3' ACTCATTGAATTGAGAAAACAATTAATTTTCATATAAGTTTTTTATTCA

BglII EcoRI HpaI

15 TATATAAATAGATCTGAATTCGTT 3' ATI3
 ATATATTTATCTAGACTTAAGCAA 5' ATI4

reconstructing the region upstream from A26L and replacing the A26L ORF with a short polylinker region containing the restriction sites BglII, EcoRI and HpaI,
 20 as indicated above. The resulting plasmid was designated pSD485. Since the BglII and EcoRI sites in the polylinker region of pSD485 are not unique, unwanted BglII and EcoRI sites were removed from plasmid pSD483 (described above) by digestion with BglII (pos. 140,136)
 25 and with EcoRI at the pUC/vaccinia junction, followed by blunt ending with Klenow fragment of *E. coli* polymerase and ligation. The resulting plasmid was designated pSD489. The 1.8 kb ClaI (pos. 137,198)/EcoRV (pos. 139,048) fragment from pSD489 containing the A26L ORF was
 30 replaced with the corresponding 0.7 kb polylinker-containing ClaI/EcoRV fragment from pSD485, generating pSD492. The BglII and EcoRI sites in the polylinker region of pSD492 are unique.

A 3.3 kb BglII cassette containing the *E. coli*
 35 Beta-galactosidase gene (Shapira et al., 1983) under the control of the vaccinia 11 kDa promoter (Bertholet et al., 1985; Perkus et al., 1990) was inserted into the BglII site of pSD492, forming pSD493KGB. Plasmid pSD493KGB was used in recombination with rescuing virus
 40 vP553. Recombinant vaccinia virus, vP581, containing

Beta-galactosidase in the A26L deletion region, was isolated as a blue plaque in the presence of X-gal.

To generate a plasmid for the removal of Beta-galactosidase sequences from vaccinia recombinant virus vP581, the polylinker region of plasmid pSD492 was deleted by mutagenesis (Mandecki, 1986) using synthetic oligonucleotide MPSYN177 (SEQ ID NO:14) (5' AAAATGGGCGTGGATTGTTAACTTTATATAACTTATTTTTGAATATAC 3'). In the resulting plasmid, pMP494Δ, vaccinia DNA encompassing positions [137,889 - 138,937], including the entire A26L ORF is deleted. Recombination between the pMP494Δ and the Beta-galactosidase containing vaccinia recombinant, vP581, resulted in vaccinia deletion mutant vP618, which was isolated as a clear plaque in the presence of X-gal.

Construction of Plasmid pSD467 for Deletion of Hemagglutinin Gene (A56R). Referring now to FIG. 4, vaccinia SalI G restriction fragment (pos. 160,744-173,351) crosses the HindIII A/B junction (pos. 162,539). pSD419 contains vaccinia SalI G cloned into pUC8. The direction of transcription for the hemagglutinin (HA) gene is indicated by an arrow in FIG. 4. Vaccinia sequences derived from HindIII B were removed by digestion of pSD419 with HindIII within vaccinia sequences and at the pUC/vaccinia junction followed by ligation. The resulting plasmid, pSD456, contains the HA gene, A56R, flanked by 0.4 kb of vaccinia sequences to the left and 0.4 kb of vaccinia sequences to the right. A56R coding sequences were removed by cutting pSD456 with RsaI (partial; pos. 161,090) upstream from A56R coding sequences, and with EagI (pos. 162,054) near the end of the gene. The 3.6 kb RsaI/EagI vector fragment from pSD456 was isolated and ligated with annealed synthetic oligonucleotides MPSYN59 (SEQ ID NO:15), MPSYN62 (SEQ ID NO:16), MPSYN60 (SEQ ID NO:17), and MPSYN 61 (SEQ ID NO:18)

- RsaI
- MPSYN59 5' ACACGAATGATTTTCTAAAGTATTTGGAAAGTTTTATAGGTAGTTGATAGA-
 MPSYN62 3' TGTGCTTACTAAAAGATTTTCATAAACCTTTCAAAATATCCATCAACTATCT 5'
- MPSYN59 -ACAAAATACATAATTT 3'
- BglII
- 10 MPSYN60 5' TGTA AAAAATAAAATCACTTTTTATACTAAGATCT-
 MPSYN61 3' TGTTTTATGTATTA AAAACATTTTTATTTAGTGAAAAATATGATTCTAGA-
- SmaI PstI EagI
- MPSYN60 -CCCGGGCTGCAGC 3'
 15 MPSYN61 -GGGCCCCGACGTCGCCGG 5'

reconstructing the DNA sequences upstream from the A56R ORF and replacing the A56R ORF with a polylinker region as indicated above. The resulting plasmid is pSD466.

- 20 The vaccinia deletion in pSD466 encompasses positions [161,185-162,053]. The site of the deletion in pSD466 is indicated by a triangle in FIG. 4.

- A 3.2 kb BglII/BamHI (partial) cassette containing the *E. coli* Beta-galactosidase gene (Shapira et al., 1983) under the control of the vaccinia 11 kDa promoter (Bertholet et al., 1985; Guo et al., 1989) was inserted into the BglII site of pSD466, forming pSD466KBG. Plasmid pSD466KBG was used in recombination with rescuing virus vP618. Recombinant vaccinia virus, vP708, containing Beta-galactosidase in the A56R deletion, was isolated as a blue plaque in the presence of X-gal.

- Beta-galactosidase sequences were deleted from vP708 using donor plasmid pSD467. pSD467 is identical to pSD466, except that EcoRI, SmaI and BamHI sites were removed from the pUC/vaccinia junction by digestion of pSD466 with EcoRI/BamHI followed by blunt ending with Klenow fragment of *E. coli* polymerase and ligation. Recombination between vP708 and pSD467 resulted in recombinant vaccinia deletion mutant, vP723, which was isolated as a clear plaque in the presence of X-gal.

Construction of Plasmid pMPCSK1A for Deletion of Open Reading Frames [C7L-K1L]. Referring now to FIG. 5, the following vaccinia clones were utilized in the construction of pMPCSK1A. pSD420 is SalI H cloned into pUC8. pSD435 is KpnI F cloned into pUC18. pSD435 was cut with SphI and religated, forming pSD451. In pSD451, DNA sequences to the left of the SphI site (pos. 27,416) in HindIII M are removed (Perkus et al., 1990). pSD409 is HindIII M cloned into pUC8.

To provide a substrate for the deletion of the [C7L-K1L] gene cluster from vaccinia, *E. coli* Beta-galactosidase was first inserted into the vaccinia M2L deletion locus (Guo et al., 1990) as follows. To eliminate the BglII site in pSD409, the plasmid was cut with BglII in vaccinia sequences (pos. 28,212) and with BamHI at the pUC/vaccinia junction, then ligated to form plasmid pMP409B. pMP409B was cut at the unique SphI site (pos. 27,416). M2L coding sequences were removed by mutagenesis (Guo et al., 1990; Mandecki, 1986) using synthetic oligonucleotide.

BglII

MPSYN82 (SEQ ID NO:19) 5'
TTTCTGTATATTGCACCAATTTAGATCTTACTCAAAA
TATGTAACAATA 3'

The resulting plasmid, pMP409D, contains a unique BglII site inserted into the M2L deletion locus as indicated above. A 3.2 kb BamHI (partial)/BglII cassette containing the *E. coli* Beta-galactosidase gene (Shapira et al., 1983) under the control of the 11 kDa promoter (Bertholet et al., 1985) was inserted into pMP409D cut with BglII. The resulting plasmid, pMP409DBG (Guo et al., 1990), was used as donor plasmid for recombination with rescuing vaccinia virus vP723. Recombinant vaccinia virus, vP784, containing Beta-galactosidase inserted into the M2L deletion locus, was isolated as a blue plaque in the presence of X-gal.

A plasmid deleted for vaccinia genes [C7L-K1L] was assembled in pUC8 cut with SmaI, HindIII and blunt

ended with Klenow fragment of *E. coli* polymerase. The left flanking arm consisting of vaccinia HindIII C sequences was obtained by digestion of pSD420 with XbaI (pos. 18,628) followed by blunt ending with Klenow
5 fragment of *E. coli* polymerase and digestion with BglII (pos. 19,706). The right flanking arm consisting of vaccinia HindIII K sequences was obtained by digestion of pSD451 with BglII (pos. 29,062) and EcoRV (pos. 29,778). The resulting plasmid, pMP581CK is deleted for vaccinia
10 sequences between the BglII site (pos. 19,706) in HindIII C and the BglII site (pos. 29,062) in HindIII K. The site of the deletion of vaccinia sequences in plasmid pMP581CK is indicated by a triangle in FIG. 5.

To remove excess DNA at the vaccinia deletion
15 junction, plasmid pMP581CK, was cut at the NcoI sites within vaccinia sequences (pos. 18,811; 19,655), treated with Bal-31 exonuclease and subjected to mutagenesis (Mandecki, 1986) using synthetic oligonucleotide MPSYN233 (SEQ ID NO:20)
20 5' TGTCATTTAACACTATACTCATATTAATAAAAATAATATTTATT 3'.

The resulting plasmid, pMPCSK1Δ, is deleted for vaccinia sequences positions 18,805-29,108, encompassing 12 vaccinia open reading frames [C7L - K1L]. Recombination between pMPCSK1Δ and the Beta-galactosidase containing
25 vaccinia recombinant, VP784, resulted in vaccinia deletion mutant, VP804, which was isolated as a clear plaque in the presence of X-gal.

Construction of Plasmid pSD548 for Deletion of Large Subunit, Ribonucleotide Reductase (I4L). Referring
30 now to FIG. 6, plasmid pSD405 contains vaccinia HindIII I (pos. 63,875-70,367) cloned in pUC8. pSD405 was digested with EcoRV within vaccinia sequences (pos. 67,933) and with SmaI at the pUC/vaccinia junction, and ligated, forming plasmid pSD518. pSD518 was used as the source of
35 all the vaccinia restriction fragments used in the construction of pSD548.

The vaccinia I4L gene extends from position 67,371-65,059. Direction of transcription for I4L is indicated by an arrow in FIG. 6. To obtain a vector plasmid fragment deleted for a portion of the I4L coding sequences, pSD518 was digested with BamHI (pos. 65,381) and HpaI (pos. 67,001) and blunt ended using Klenow fragment of *E. coli* polymerase. This 4.8 kb vector fragment was ligated with a 3.2 kb SmaI cassette containing the *E. coli* Beta-galactosidase gene (Shapira et al., 1983) under the control of the vaccinia 11 kDa promoter (Bertholet et al., 1985; Perkus et al., 1990), resulting in plasmid pSD524KBG. pSD524KBG was used as donor plasmid for recombination with vaccinia virus VP804. Recombinant vaccinia virus, VP355, containing Beta-galactosidase in a partial deletion of the I4L gene, was isolated as a blue plaque in the presence of X-gal.

To delete Beta-galactosidase and the remainder of the I4L ORF from VP355, deletion plasmid pSD548 was constructed. The left and right vaccinia flanking arms were assembled separately in pUC8 as detailed below and presented schematically in FIG. 6.

To construct a vector plasmid to accept the left vaccinia flanking arm, pUC8 was cut with BamHI/EcoRI and ligated with annealed synthetic oligonucleotides 518A1/518A2 (SEQ ID NO:21/SEQ ID NO:22)

BamHI RsaI
 518A1 5' GATCCTGAGTACTTTGTAATATAATGATATATATTTTCACTTTATCTCAT
 518A2 3' GACTCATGAAACATTATATTACTATATATAAAAGTGAAATAGAGTA

BglII EcoRI
 TTGAGAATAAAAAGATCTTAGG 3' 518A1
 AACTCTTATTTTCTAGAATCCTTAA 5' 518A2

forming plasmid pSD531. pSD531 was cut with RsaI (partial) and BamHI and a 2.7 kb vector fragment isolated. pSD518 was cut with BglII (pos. 64,459)/ RsaI (pos. 64,994) and a 0.5 kb fragment isolated. The two fragments were ligated together, forming pSD537, which contains the complete vaccinia flanking arm left of the I4L coding sequences.

To construct a vector plasmid to accept the right vaccinia flanking arm, pUC8 was cut with BamHI/EcoRI and ligated with annealed synthetic oligonucleotides 518B1/518B2 (SEQ ID NO:23/SEQ ID NO:24)

5 BamHI BglII SmaI
 518B1 5'
 GATCCAGATCTCCCGGGAAAAAAATTATTTAACTTTTCATTAATAGGGATTT
 518B2 3' GTCTAGAGGGCCCTTTTTTAATAAATTGAAAAGTAATTATCCCTAA

10 RsaI EcoRI
 GACGTATGTAGCGTACTAGG 3' 518B1
 CTGCATACTACGCATGATCCTTAA 5' 518B2

forming plasmid pSD532. pSD532 was cut with RsaI
 15 (partial)/EcoRI and a 2.7 kb vector fragment isolated.
 pSD518 was cut with RsaI within vaccinia sequences (pos.
 67,436) and EcoRI at the vaccinia/pUC junction, and a 0.6
 kb fragment isolated. The two fragments were ligated
 together, forming pSD538, which contains the complete
 20 vaccinia flanking arm to the right of I4L coding
 sequences.

The right vaccinia flanking arm was isolated as
 a 0.6 kb EcoRI/BglIII fragment from pSD538 and ligated
 into pSD537 vector plasmid cut with EcoRI/BglIII. In the
 25 resulting plasmid, pSD539, the I4L ORF (pos. 65,047-
 67,386) is replaced by a polylinker region, which is
 flanked by 0.6 kb vaccinia DNA to the left and 0.6 kb
 vaccinia DNA to the right, all in a pUC background. The
 site of deletion within vaccinia sequences is indicated
 30 by a triangle in FIG. 6. To avoid possible recombination
 of Beta-galactosidase sequences in the pUC-derived
 portion of pSD539 with Beta-galactosidase sequences in
 recombinant vaccinia virus vP855, the vaccinia I4L
 deletion cassette was moved from pSD539 into pRC11, a pUC
 35 derivative from which all Beta-galactosidase sequences
 have been removed and replaced with a polylinker region
 (Colinas et al., 1990). pSD539 was cut with EcoRI/PstI
 and the 1.2 kb fragment isolated. This fragment was
 ligated into pRC11 cut with EcoRI/PstI (2.35 kb), forming
 40 pSD548. Recombination between pSD548 and the Beta-

galactosidase containing vaccinia recombinant, vP855, resulted in vaccinia deletion mutant vP866, which was isolated as a clear plaque in the presence of X-gal.

DNA from recombinant vaccinia virus vP866 was
 5 analyzed by restriction digests followed by
 electrophoresis on an agarose gel. The restriction
 patterns were as expected. Polymerase chain reactions
 (PCR) (Engelke et al., 1988) using vP866 as template and
 primers flanking the six deletion loci detailed above
 10 produced DNA fragments of the expected sizes. Sequence
 analysis of the PCR generated fragments around the areas
 of the deletion junctions confirmed that the junctions
 were as expected. Recombinant vaccinia virus vP866,
 containing the six engineered deletions as described
 15 above, was designated vaccinia vaccine strain "NYVAC."

Example 2 - PLASMID CONSTRUCTIONS

Construction of Fowlpox Insertion Plasmid at F8
Locus. Plasmid pRW731.15 contains a 10 Kbp PvuII-PvuII
 fragment cloned from TROVAC genomic DNA. The nucleotide
 20 sequence was determined on both strands for a 3660 bp
 PvuII-EcoRV fragment. This sequence is as follows (SEQ
 ID NO:25):

```

      1  GATATCTGTG GTCTATATAT ACTACACCCT ACCGATATTA ACCAACGAGT
      2  TCTCACAAG
  25   61  AAAACTTGTT TAGTAGATAG AGATTCTTTG ATTGTGTTTA AAAGAAGTAC
      3  CAGTAAAAAG
      4  121 TGTGGCATAT GCATAGAAGA AATAAACAAA AAACATATTT CGAACAGTA
      5  TTTTGGAATT
      6  181 CTCCCAAGTT GTAAACATAT TTTTGCCTA TCATGTATAA GACGTTGGGC
  30   AGATACTACC
      7  241 AGAAATACAG ATACTGAAAA TACGTGTCCT GAATGTAGAA TAGTTTTTCC
      8  TTTCATAATA
      9  301 CCCAGTAGGT ATTGGATAGA TAATAAATAT GATAAAAAAA TATTATATAA
     10  TAGATATAAG
  35   361 AAAATGATTT TTACAAAAAT AACCTATAAG AACAATAAAA ATATAATTAC
     11  ATTTACGGAA
     12  421 AATAGCTGGT TTTAGTTTAC CAACTTAGAG TAATTATCAT ATTGAATCTA
     13  TATTGTTTTT
     14  481 TAGTTATATA AAAACATGAT TAGCCCCCAA TCGGATGAAA ATATAAAAGA
  40   TGTTGAGAAT
     15  541 TTCGAATACA ACAAAAAGAG GAATCGTACG TTGTCCATAT CCAAACATAT
     16  AAATAAAAAT
  
```

601 TCAAAAGTAG TATTATACTG GATGTTTGA GATCAACGTG TACAAGATAA
 TTGGGCTTTA
 661 ATTTACGCAC AACGATTAGC GTTAAAACTC AAAATACCTC TAAGAATATG
 CTTTTGTGTC
 5 721 GTGCCAAAAT TTCACACTAC TACTTCTAGA CACTTTATGT TTTAATATC
 CGGTCTTAAA
 781 GAAGTCGCGG AAGAATGTAA AAGACTATGT ATAGGGTTTT CATTGATATA
 TGGCGTACCA
 841 AAAGTAATAA TTCCGTGTAT AGTAAAAAA TACAGAGTCG GAGTAATCAT
 10 AACGGATTTC
 901 TTTCCATTAC GTGTTCCCGA AAGATTAATG AACAGACTG TAATATCTCT
 TCCAGATAAC
 961 ATACCTTTTA TACAAGTAGA CGCTCATAAT ATAGTACCTT GTTGGGAAGC
 TTCTGATAAA
 15 1021 GAAGAATACG GTGCACGAAC TTTAAGAAAA AAGATATTTG ATAAATTATA
 TGAATATATG
 1081 ACAGAATTC CTGTTGTTG TAAACATCCA TACGGTCCAT TTTCTATATC
 TATTGCAAAA
 1141 CCCAAAAATA TATCATTAGA CAAGACGGTA TTACCCGTAA AATGGGCAAC
 20 GCCTGGAACA
 1201 AAAGCTGGAA TAATTGTTTT AAAAGAATTT ATAAAAACA GATTACCGTC
 ATACGACGCG
 1261 GATCATAACA ATCCTACGTG TGACGCTTTG AGTAACTTAT CTCCGTGGCT
 ACATTTTGGT
 25 1321 CATGTATCCG CACAACGTGT TGCCTTAGAA GTATTAATAT GTATACGAGA
 AAGCAAAAAA
 1381 AACGTTGAAA CGTTTATAGA TGAAATAATT GTAAGAAGAG AACTATCGGA
 TAAATTTTGT
 1441 TACTATAACA AACATTATGA TAGTATCCAG TCTACTCATT CATGGGTTAG
 30 AAAACATTA
 1501 GAAGATCACA TTAATGATCC TAGAAAGTAT ATATATTCCA TTAACAACCT
 CGAAAAAGCG
 1561 GAACTCATG ATCCTCTATG GAACGCGTCA CAAATGCAGA
 TGGTGAGAGA AGGAAAAATG
 35 1621 CATAGTTTTT TACGAATGTA TTGGGCTAAG AAGATACTTG AATGGACTAG
 AACACCTGAA
 1681 GACGCTTTGA GTTATAGTAT CTATTTGAAC AACAAGTACG AACTAGACGG
 CACGGATCCT
 1741 AACGGATACG TAGGTTGTAT GTGGTCTATT TGCGGATTAC ACGATAGAGC
 40 GTGGAAAGCA
 1801 AGACCGATAT TTGGAAAC AT AAGATATATG AATTATGAGA GTTCTAAGAA
 GAAATTTGAT
 1861 GTTGCTGTAT TTATACAGAA ATACAATTAA GATAAATAAT ATACAGCATT
 GTAACCATCG
 45 1921 TCATCCGTTA TACGGGGAAT AATATTACCA TACAGTATTA TTAAATTTTC
 TTACGAAGAA
 1981 TATGATCGG TATTTATCGT TAGTTTATTT TACATTTATT AATTAAACAT
 GTCTACTATT
 2041 ACCTGTTATG GAAATGACAA ATTTAGTTAT ATAATTTATG ATAAATTAA
 50 GATAATAATA
 2101 ATGAAATCAA ATAATTATGT AAATGCTACT AGATTATGTG AATTACGAGG
 AAGAAAGTTT

2161 ACGAACTGGA AAAAATTAAG TGAATCTAAA ATATTAGTCG ATAATGTAAA
AAAAATAAAT
2221 GATAAACTA ACCAGTTAAA AACGGATATG ATTATATACG TTAAGGATAT
TGATCATAAA
5 2281 GGAAGAGATA CTTGCGGTTA CTATGTACAC CAAGATCTGG TATCTTCTAT
ATCAAATTGG
2341 ATATCTCCGT TATTCGCCGT TAAGGTAAAT AAAATTATTA ACTATTATAT
ATGTAATGAA
2401 TATGATATAC GACTTAGCGA AATGGAATCT GATATGACAG AAGTAATAGA
10 TGAGTTGAT
2461 AAATTAGTAG GAGGATACAA TGATGAAATA GCAGAAATAA TATATTTGTT
TAATAAATTT
2521 ATAGAAAAAT ATATTGCTAA CATATCGTTA TCAACTGAAT TATCTAGTAT
ATTAAATAAT
15 2581 TTTATAAATT TTATAAATTT TAATAAAAAA TACAATAACG ACATAAAGAT
ATTTAATCTT
2641 TAATTCTTGA TCTGAAAAAC ACATCTATAA AACTAGATAA AAAGTTATTC
GATAAAGATA
2701 ATAATGAATC GAACGATGAA AAATTGGAAA CAGAAGTTGA TAAGCTAATT
20 TTTTTCATCT
2761 AAATAGTATT ATTTTATTGA AGTACGAAGT TTTACGTTAG ATAAATAATA
AAGGTCGATT
2821 TTTACTTTGT TAAATATCAA ATATGTCATT ATCTGATAAA GATACAAAAA
CACACGGTGA
25 2881 TTAACAACCA TCTAACGAAC AGATATTACA AAAAATACGT CGGACTATGG
AAAACGAAGC
2941 TGATAGCCTC AATAGAAGAA GCATTAAAGA AATTGTTGTA GATGTTATGA
AGAATTGGGA
3001 TCATCCTCAA CGAAGAAATA GATAAAGTTC TAAACTGGAA AAATGATACA
30 TTAAACGATT
3061 TAGATCATCT AAATACAGAT GATAATATTA AGGAAATCAT ACAATGTCTG
ATTAGAGAAT
3121 TTGCGTTTAA AAAGATCAAT TCTATTATGT ATAGTTATGC TATGGTAAAA
CTCAATTCAG
35 3181 ATAACGAACA TTGAAAGATA AAATTAAGGA TTATTTTATA GAACTATTC
TTAAAGACAA
3241 ACGTGGTTAT AAACAAAAGC CATTACCCGG ATTGGAAACT AAAATACTAG
ATAGTATTAT
3301 AAGATTTTAA AAACATAAAA TTAATAGGTT TTTATAGATT GACTTATTAT
40 ATACAATATG
3361 GATAAAAGAT ATATATCAAC TAGAAAGTTG AATGACGGAT TCTTAATTTT
ATATTATGAT
3421 TCAATAGAAA TTATTGTCAT GTCGTGTAAT CATTTTATAA ATATAACAGC
GTTACTAGCT
45 3481 AAGAAAAACA AGGACTTTAA TGAATGGCTA AAGATAGAAT CATTTAGAGA
AATAATAGAT
3541 ACTTTAGATA AAATTAAATTA CGATCTAGGA CAACGATATT GTGAAGAACT
TACGGCGCAT
3601 CACATTCCAG TGTAATTATT GAGGTCAAAG CTAGTAACTT AATAGATGAC
50 AGGACAGCTG

The limits of an open reading frame designated as F8 were determined within this sequence. The open reading frame is initiated at position 496 and terminates at position 1887. The engineered deletion was made from
5 position 780 to position 1927, as described below.

Plasmid pRW761 is a sub-clone of pRW731.15 containing a 2429 bp EcoRV-EcoRV fragment. Plasmid pRW761 was completely digested with XbaI and partially digested with SspI. A 3700 bp XbaI-SspI band was
10 isolated and ligated with the annealed double-stranded oligonucleotides JCA017 (SEQ ID NO:26) and JCA018 (SEQ ID NO:27).

JCA017:
15 CTAGACACTTTATGTTTTTAAATATCCGGTCTTAAAAGCTTCCCGGGGATCCTTA
TACGGGGAATAAT 3'

JCA018:
ATTATCCCCGTATAAGGATCCCCCGGGAAGCTTTTAAGACCGGATATTAAAAA
20 CATAAAGTGT 3'

The plasmid resulting from this ligation was designated pJCA002.

Additional cloning sites were incorporated into pJCA002 by inserting the annealed and kinased
25 oligonucleotides CE205 (SEQ ID NO:28) and CE206 (SEQ ID NO:29) into the BamHI and HindIII sites of pJCA002 to form pCE72.

CE205:
30 GATCAGAAAACTAGCTAGCTAGTACGTAGTTAACGTCGACCTGCAGAAGCTTCT
AGCTAGCTAGTTTTAT

CE206:
AGCTATAAAAACTAGCTAGCTAGTAGAAGCTTCTGCAGGCTCGACGTTAACTACGTAC
35 TAGCTAGCTAGTTTTCT

In order to increase the length of the FPV flanking arms in the insertion plasmid, plasmid pJCA021 was constructed. Plasmid pJCA021 was obtained by inserting a 4900bp PvuII-HindII fragment from PRW 731.15
40 (previously described) into the SmaI and HindII sites of pBluescript SS K⁺ (Stratagene, La Jolla, California). A

BglII to EcoRI fragment from pCE72 was then ligated into the BglII and EcoRI sites of pJCA021 to generate pCEN100.

Construction of a Plasmid for Insertion of MDV gB Sequence into TROVAC. Three fragments generated by

- 5 the Polymerase Chain Reaction (PCR) were necessary for construction of an insertion plasmid. Reaction 1 created a fragment which contained the vaccinia virus H6 promoter fused in a precise ATG:ATG configuration with the 5' end of the MDV gB gene. For this reaction, plasmid pRW825
10 containing the H6 promoter previously described (Taylor et al., 1988a,b; Guo et al., 1989) was used as a template and oligonucleotides RW297 (SEQ ID NO:30) and RW298 (SEQ ID NO:31) as primers.

RW297: GACCTCGTCGACAATACGACTCACTATAGGGAG

- 15 RW298:

GAAGAATATGCAATTCGCGCTAAAATAGTGCATTACGATACAACTTAA

- Reaction 2 generated a fragment containing the 5' end of the MDV gB gene in which a TTTTTTT sequence was changed to TATTCTT to eliminate the possibility of early
20 termination (Yuen and Moss, 1987). The 3' end of the fragment generated, overlapped the 5' end of the fragment generated in reaction 3. In reaction 2, plasmid pUC13gB containing the MDV gB coding sequence was used as a template and oligonucleotides RW299 (SEQ ID NO:32) and
25 RW300 (SEQ ID NO:33) as primers.

RW299: ATGCACTATTTTAGGCGGAATTGCATATTCTTCCTTATAGTTATTC

RW300: ATATCTACGATGATTTTCTAGGTTCGGGACATTTTC

- Reaction 3 generated a fragment defining the 3' end of the MDV gB gene and removed non-coding sequences
30 contained in pUC13gB. Plasmid pUC13gB was used as a template for this reaction and RW 301 (SEQ ID NO:34) and RW302 (SEQ ID NO:35) as primers.

RW301: GTCCCGAACCTAGAAAATCATCGTAGATATTTTCTG

RW302: CCTCAGGAATTCGTCGACTATTTACACAGCATCATCTTCTGAG

- 35 Products of these three PCR reactions were pooled and used as a template for primers RW297 (SEQ ID NO:30) and RW302 (SEQ ID NO:35) in a fourth PCR. The

final 1250 bp PCR product was isolated, cut with HincII and inserted into plasmid pCEN100 which had been cut with HincII to derive pRW871. Derivation of plasmid pCEN100 which contains TROVAC genomic DNA directing insertion to the F8 locus is described above. Plasmid pRW871 was partially cut with XbaI, the linear product isolated, recut with AflII and the 7.7 kbp fragment was isolated. Plasmid pUC13gB was digested with AflII and XbaI and the resulting 2140bp fragment containing the gB coding region was inserted into the 7.7 kbp fragment derived from pRW871. The resulting plasmid, pRW878, was used in *in vitro* recombination with TROVAC as the rescuing virus to derive recombinant vFP108.

Construction of a Plasmid for Insertion of MDV gB into Vaccinia Virus. Plasmid pRW878, previously described, was digested with HincII and the 2.8 kbp fragment containing the MDV gB coding sequence linked to the vaccinia virus H6 promoter was inserted at the SmaI site of vaccinia insertion plasmid pSD553VC to derive plasmid pRW879. Plasmid pSD553VC is an insertion plasmid utilizing the host range selection system described in Perkus et al. (1989). In this plasmid, the vaccinia virus K1L gene and polylinker regions are located within flanking Copenhagen vaccinia arms, replacing the ATI region (open reading frames A25L and A26L) described in Goebel et al. (1990a,b). The entire region is in a pUC8 vector and insertion sites are flanked by translational stop codons and transcriptional stop signals. Plasmid pRW879 was used in *in vitro* recombination with NYVAC (vP866) as the rescuing virus to derive recombinant vP935 expressing the Marek's gB gene.

Construction of a Plasmid for Insertion of MDV gD into Vaccinia Virus. Four PCR reactions were used to create an insertion plasmid. In reaction 1, plasmid pRW880 was used as a template to derive a fragment containing the vaccinia virus H6 promoter sequence linked to the MDV gD 5' sequence with the promoter's ATG

overlapping the initiating ATG of the MDV gD gene.
 Plasmid pRW880 contains the previously described H6
 promoter sequence linked to a non-pertinent gene in the
 F16 insertion locus. The primers used in this reaction
 5 were RW389 (SEQ ID NO:36) and RW390 (SEQ ID NO:37).
 RW 389: TGAGATATATCTAAAGAAGAATACTTTCATTACGATACAAACTTAAC
 RW 390: TAATATAATCTTTTATAC

In the second and third PCR reactions, pMDV517
 was used as a template. Plasmid pMDV517 contains a 5.2
 10 kb DNA fragment containing the MDV gD gene inserted at
 the EcoRI site of pUC13. The object of the reactions was
 to change two internal TTTTNT signals to eliminate the
 possibility of premature termination (Yuen and Moss,
 1987). In reaction two, oligonucleotides RW386 (SEQ ID
 15 NO:38) and RW 391 (SEQ ID NO:39) were used as primers to
 change TTTTTTTT to TTCTTCTT.

RW386: CCGTTCAGCTTCTTCGTCAATGGTACAACACGGCTGTTAGAC
 RW391: GAGCGGTCGACAAGCTTATAGGCGGGAATATGC

In reaction three, oligonucleotides RW387 (SEQ
 20 ID NO:40) and RW388 (SEQ ID NO:41) were used to alter the
 sequence TTTTTTTGT to CTTCTTCGT.

RW387:
 TGTTGTACCATTGACGAAGAAGCTGAACGGTTTGCATAGTTTGTTATC
 RW388: ATGAAAGTATTCTTCTTTAGATATATCTCATCCAC

25 The products of the three PCR reactions were
 pooled and primed with RW390 (SEQ ID NO:37) and RW391
 (SEQ ID NO:39) for a fourth PCR reaction. The product of
 the final PCR reaction was cut with NruI and HindIII,
 resulting in a 1.2 kbp fragment containing the 3' end of
 30 the H6 promoter and the MDV gD coding sequence. Plasmid
 pRW880 (derivation described below) was digested with
NruI and HindIII (which eliminates the non-pertinent gene
 leaving the 5' end of the H6 promoter), and ligated with
 the 1.2 kp fragment obtained after digestion of the final
 35 PCR product. The resulting plasmid pRW893 was then
 digested with NotI, releasing a 1.4 kbp fragment
 containing the H6 promoted MDV gD gene which was

inserted into the SmaI site of pSD533VC previously described to generate pRW894. Plasmid pRW894 was used in in vitro recombination with NYVAC (vP866) as the rescuing virus to generate recombinant vP1005 expressing the Marek's gD gene.

Construction of a Fowlpox Insertion Plasmid at the F16 Locus. Plasmid pFP23K-1 contains the 10.5 Kbp HindIII fowlpox DNA fragment described in Tartaglia et al. (1990). Plasmid pFP23K-1 was used as a template for a PCR reaction using the following primers RW264 (SEQ ID NO:42), RW265 (SEQ ID NO:43), RW266 (SEQ ID NO:44) and RW267 (SEQ ID NO:45).

RW264: AATTAACCCGGGATCCAAGCTTCTAGCTAGCTAATTTT
ATAGCGGCCGCTATAATCGTAACTTATTAG

RW265: CTAGCTAGAAGCTTGGATCCCGGGTTAATTAATTAATAAAAA
GCGGCCGCGTTAAAGTAGAAAAAATG

RW266: GTTACATATGTACAGAATCTGATCATAG

RW267: GCTAGAATTCTCTTAGTTTTATAGTTG

Primers RW264 and RW267 primed the first reaction. Primers RW265 and RW266 primed the second reaction. RW266, RW267 and the two products from reactions 1 and 2 were combined for a final PCR. Orientation of the primers on the template is as follows:

	RW266	RW265	RW264	RW267
30	---->	<--- --->	<--	
	_____Template			
35	<u>NdeI</u> site			<u>EcoRI</u> site

Primer RW266 begins at position 9883 within the 10.5 kbp sequence with an NdeI site. The 5' ends of RW265 and RW264 overlap and are reverse complements. RW265 and RW264 replace the A at position 10054 bp with 61 bp containing the insertion sites SmaI, BamHI and HindIII. Translation termination codons and

transcription stop signals flank the insertion sites. The 5' end of RW267 is at position 10229 bp beginning with an EcoRI site.

The third and final PCR product was cut with
5 NdeI and EcoRI and inserted between the NdeI and EcoRI
sites of pRW715, resulting in pRW864. Plasmid pRW715 is
plasmid pUC9 cut with PvuII and an EcoRI linker was
inserted in place of the 300 bp PvuII fragment. In order
to insert the *E. coli* LacZ gene plasmid pAMIBG was
10 utilized. Plasmid pAMIBG contains the LacZ BamHI
fragment from pMC1871 (Casadaban et al., 1983) inserted
in the previously described BamHI site 3' of the 11K
vaccinia virus promoter (Paoletti et al., 1984). Plasmid
pAMIBG was partially cut with BamHI, the linear product
15 isolated and cut with PstI. The PstI-BamHI fragment
containing the 11K promoted LacZ gene was blunt-ended and
ligated into the SmaI site of pRW864 (described above).
The resulting plasmid was designated pRW867A.

Plasmid pRW866 is a subclone of plasmid pFP23K-
20 1 which contains the 10.5 kbp fowlpox DNA fragment
described in Tartaglia et al. (1990). Plasmid pRW866 was
constructed by insertion of a 7.3 kpb NaeI to NdeI
fowlpox fragment from pFP23K-1 between the PvuII and NdeI
sites of pUC9. Plasmid pRW866 contains two FspI sites;
25 one is in pUC and the second at position 1955bp defines
the intergenic insertion site designated F16. The FspI
insertion locus does not interrupt any open reading frame
containing an ATG. The linear product of a partial
digestion of pRW866 with FspI was isolated and ligated to
30 a 3.3 kpb NotI fragment from pRW867A containing the 11k
promoted LacZ gene. This allowed insertion of the blunt
ended LacZ gene fragment into the FspI intergenic
insertion site, creating plasmid pRW868. The LacZ gene
in pRW868 was then replaced with the 61 bp fragment
35 (previously described) containing SmaI, BamHI and HindIII
sites and flanked by transcription termination and
translation stop sequences used in development of pRW864.

This replacement resulted in plasmid pRW813. Plasmid pRW880 used as a template for the initial construction of plasmid pRW894 contains a non-pertinent gene linked to the H6 promoter in the SmaI site of the F16 insertion locus.

Example 3 - DEVELOPMENT OF POXVIRUS BASED RECOMBINANT
EXPRESSING MDV GLYCOPROTEINS

Plasmids previously described were transfected into NYVAC or TROVAC infected cells by using the calcium phosphate precipitation method previously described (Panicali and Paoletti, 1982; Piccini et al., 1987). Positive plaques were selected on the basis of hybridization to specific MDV radiolabelled probes and subjected to sequential rounds of plaque purification until a pure population was achieved. Representative plaques from each IVR were then amplified and a stock virus established.

Indirect immunofluorescence was performed as described in Taylor et al. (1990) using a polyclonal chicken anti-MDV serum designated chicken #392.

Immunoprecipitation reactions were performed as described in Taylor et al. (1990) using the reagent described above.

NYVAC Recombinants Expressing MDV

Glycoproteins. Transfection of plasmid pRW879 led to the development of NYVAC recombinant vP935.

Immunofluorescence analysis indicated that a protein recognized by MDV immune serum was expressed on the infected cell surface. Immunoprecipitation analysis using the same immune serum from chicken detected the presence of three major expression products with the approximate molecular weights of 110 kDa, 64 kDa and 48 kDa. These sizes correspond to expected products of the MDV gB gene.

Transfection of plasmid pRW894 led to the development of NYVAC recombinant vP1005. A plaque immunoscreen assay indicated that a protein recognized by

MDV immune serum was expressed on the infected cell surface. Immunoprecipitation analysis indicated the production of two products with molecular weights of approximately 45 kDa (corresponding to the precursor form of the protein) and 65 kDa which represents the processed glycoprotein.

TROVAC Recombinant Expressing the gB Glycoprotein. Transfection of plasmid pRW878 led to the development of recombinant vFP108. Immunofluorescence analysis indicated that a protein recognized by MDV immune serum was expressed on the infected cell surface. Immunoprecipitation analysis using the same immune serum from chickens demonstrated the presence of three major expression products with approximate molecular weights of 110 kDa, 64 kDa and 48 kDa.

Example 4 - IMMUNIZATION OF CHICKENS AND SUBSEQUENT CHALLENGE

A group of 25 one day old SPF chickens were inoculated by the subcutaneous route with one dose of $4.0 \log_{10}$ pfu of TROVAC-MDV gB (vFP108). Ten SPF birds remained uninoculated. At 14 days, the birds including 10 non-vaccinated controls, were challenged by intraperitoneal inoculation of a dilution of the JMV tumor cell line (Nazerian et al., 1977) previously determined to cause 100% mortality, and survivors were assessed.

Results of protection are shown in Table 1.

Table 1
Protective Efficacy of TROVAC-MDV gB (vFP108)
in SPF Chickens

5	Treatment Group	Protection Ratio Survivors/Total	% Survival
	vFP108 ^a	11/25	44
	Non-vaccinated controls	0/10	0
10	^a : Birds inoculated with 4.0 log ₁₀ pfu of vFP108. Birds challenged at 14 days by inoculation with JMV tumor cell line.		

15 In a second experiment, 20 Rhode Island Red Chicks hatched in isolators and free from maternal antibodies to MDV, herpesvirus of turkeys (HVT) and other avian pathogens were vaccinated intramuscularly at one day of age with 6.3 log₁₀ pfu of fowlpox recombinant vFP108. Seven days later the chicks were challenged with MDV by contact infection. This was achieved by mixing the vaccinated chicks with 8 chickens inoculated 15 days previously with 3.0 log₁₀ pfu of the RB1-B strain of MDV. A second group of 20 unvaccinated chicks derived from the same hatch served as controls. These were also challenged with MDV by contact as above. The two groups were kept in separate cages in a high security containment room. A third group of 20 unvaccinated chicks were challenged by inoculation with 3.0 log₁₀ pfu of RB1-B and kept in a separate room. This group was included in the experiment to compare the efficiency of challenge by the two methods.

The chicks were observed daily and those that died were examined for gross Marek's disease lesions in visceral organs and peripheral nerves. Tissue samples were taken for histological examination in cases where gross Marek's disease lesions were not obvious.

Two chicks in the group vaccinated with fowlpox recombinant showed symptoms of eye infection, probably due to fowlpox, and died within 2 days after contact with MDV-infected chicks. They were eliminated from the
5 experiment and do not appear in the mortality results shown in Table 2 and Fig. 7.

The results show that vaccination with the fowlpox recombinant delayed mortality significantly. The mean time to death in the vaccinated and unvaccinated
10 group (contact challenge) was 56 days and 35 days respectively. The difference was significant ($P < 0.005$) as shown by analysis of the log transformation of the data using Student's t test.

The total mortality in the two groups after a
15 prolonged period of 19 weeks did not differ significantly as shown by a Chi-square test. However at 6 to 7 weeks post-vaccination, mortality rates differed significantly being almost 100% in the controls and 10% in the vaccinated birds. It should be noted that Broiler
20 chickens are normally sent to market at 6 to 7 weeks of age.

It is clear from Fig. 7 that the challenge by contact infection was efficient compared to challenge by inoculation. The total mortality in the two groups was
25 similar and the slopes of the cumulative mortality curves were also similar after a delay of about 2 weeks (contact infection), which probably represented the time required to establish infection.

It should be noted that the vaccinated group
30 was continuously exposed to MDV shed by the unvaccinated group which was kept in the same room.

In conclusion, the importance of MDV gB as a protective immunogen has been demonstrated under rigorous conditions which involved the use of genetically
35 susceptible chickens vaccinated at one day old, and challenged with MDV by two different methods.

36

Table 2

Time to death (days)

	Fowlpox vaccinated contact challenge	Unvaccinated contact challenge	Unvaccinated inoc. challenge
5	46	36	10
	44	17	26
	110	32	39
	77	48	26
	97	64	42
10	53	47	28
	41	31	32
	35	45	24
	56	33	24
	52	32	33
15	57	13	10
	51	33	34
		48	22
		50	10
		27	42
20		45	9
		35	29
		40	24
		38	
25	Number	12	19
	Mean	56	35
30	Total chicks per group	18	20
			19

The results indicate the potential of TROVAC-MDV recombinants for vaccination against MDV in the poultry industry. The restricted host range of fowlpox virus provides an inherent safety barrier to transmission of recombinant to non-avian species. Use of antigenic regions of MDV rather than the whole virus eliminates the need to introduce live herpes virus into the environment. The ability of TROVAC to incorporate large amounts of foreign genetic information should allow for inclusion of multiple antigenic determinants from a range of serotypes.

Example 5 - COMPARATIVE EFFICACY OF TROVAC-MDV
(vFP108 and HVT)

In previous experiments, the ability of TROVAC-MDV (vFP108) to protect against MDV challenge was assessed in two ways. In the first experiment, day of age SPF chickens were vaccinated with 40 log₁₀ pfu of vFP108 by the subcutaneous route in the nape of the neck. When birds were challenged at 14 days by intraperitoneal inoculation of the JMV tumor cell line, 44% of birds survived challenge. In the second experiment, day old SPF birds were vaccinated by intramuscular inoculation of 6.3 log₁₀ pfu of vFP108. Seven days later, vaccinated and unvaccinated birds were challenged by contact infection with birds infected with MDV strain RB18. Ninety percent of vaccinated birds had survived challenge at 6-7 weeks post-vaccination.

The most commonly used MDV vaccines are the Turkey herpes virus (HVT) vaccines which are serologically related to MDV. This Example shows the comparative efficacy of HVT and TROVAC-MDV (vFP108).

Twenty day old SPF birds were inoculated with 3.6 log₁₀ EID₅₀ of TROVAC-MDV (vFP108) by the subcutaneous route in the nape of the neck. Twenty chicks were inoculated with 3.0 log₁₀ pfu of a cell associated HVT vaccine by the subcutaneous route. Ten birds remained uninoculated. Five days post-inoculation, vaccinates and

controls were challenged by intraperitoneal inoculation of the RB1B challenge virus. Birds were observed for 49 days at which time they were necropsied and examined for lesions typical of Marek's disease. The results of
5 challenge are shown in Table 3.

The results indicate that 90% of non-vaccinated challenge controls succumbed to infection. Birds vaccinated with TROVAC-MDV (vFP108) showed a 75% survival rate while birds vaccinated with the HVT vaccine showed
10 an 85% survival rate. The result indicates that protection afforded by the TROVAC-MDV (vFP108) vaccine was comparable to the cell associated HVT. Thus, TROVAC-MDV is an effective vaccine.

39

Table 3

Comparative efficacy of TROVAC-MDV (vFP108) and HVT

Vaccine		Protection Ratio ^a	% Protection
5	TROVAC-MDV (vFP108)	15/20	75
	HVT	17/20	85
	None	1/10	10

10

^a Ratio of birds protected to total number challenged

REFERENCES

1. Bertholet, C., R. Drillien, and R. Wittek, Proc. Natl. Acad. Sci. USA 82, 2096-2100 (1985).
- 5 2. Bournsnell, M.E.G., P.F. Green, A.C.R. Samson, J.I.A. Campbell, A. Deuter, R.W. Peters, N.S. Millar, P.T. Emmerson, and M.M. Binns, Virology 178, 297-300 (1990a).
- 10 3. Bournsnell, M.E.G., P.F. Green, J.I.A. Campbell, A. Deuter, R.W. Peters, F.M. Tomley, A.C.R. Samson, P. Chambers, P.T. Emmerson, and M.M. Binns, J. Gen. Virol. 71, 621-628 (1990b).
- 15 4. Calnek, B.W. and R.L. Witter, In Diseases of Poultry 9th Edition, eds. B.W. Calnek, H.J. Barnes, C.W. Beard, W.M. Reid and H.W. Yoder, Jr. (Iowa State University Press, Ames, Iowa, USA) pp. 342-385 (1991).
- 20 5. Calnek, B.W., K.A. Schat, L.J.N. Ross, W.R. Shek, and C.-L.H. Chen, Int. J. Cancer 33, 389-398 (1984).
- 25 6. Calnek, B.W., K.A. Schat, E.D. Heller, and C. Buscaglia, In Proc Int Symp Marek's Dis, ed. B.W. Calnek and J.L. Spencer (Am. Assoc. Avian Pathol, Kennett Square, PA) pp. 173-187 (1985).
- 30 7. Cantin, E.M., R. Eberle, J.L. Baldick, B. Moss, D.E. Willey, A.L. Notkins and H. Openshaw, Proc. Nat. Acad. Sci USA 84, 5908-5912 (1987).
- 35 8. Casadaban, M.J., A. Martinez-Arias, S.K. Shapira, and J. Chow, Methods in Enzymology 100, 293-308 (1983).
9. Clewell, D.B., and D.R. Helinski, Proc. Natl. Acad. Sci. USA 62, 1159-1166 (1969).
- 40 10. Clewell, D.B., J. Bacteriol. 110, 667-676 (1972).
11. Colinas, R.J., R.C. Condit, and E. Paoletti, Virus Research 18, 49-70 (1990).
- 45 12. Cremer, K.J., M. Mackett, C. Wohlenberg, A.L. Notkins and B. Moss, Science 228, 737-740 (1985).
13. Edbauer, C., R. Weinberg, J. Taylor, A. Rey-Senelongue, J.F. Bouquet, P. Desmettre, and E. Paoletti, Virology 179, 901-904 (1990).
- 50 14. Engelke, D.R., P.A. Hoener, and F.S. Collins, Proc. Natl. Acad. Sci. USA 85, 544-548 (1988).
- 55

15. Esposito, J.J., Fifth Report of the International Committee on Taxonomy of Viruses, Archives of Virology Supplement 2, eds. R.I.B. Francki, C.M. Faquet, D.L. Knudson, F. Brown, (Springer-Verlag, New York) pp 91-102 (1991).
5
16. Goebel, S.J., G.P. Johnson, M.E. Perkus, S.W. Davis, J.P. Winslow, and E. Paoletti, Virology 179, 247-266 (1990a).
10
17. Goebel, S.J., G.P. Johnson, M.E. Perkus, S.W. Davis, J.P. Winslow, and E. Paoletti, Virology 179, 517-563 (1990b).
- 15 18. Guo, P., S. Goebel, M.E. Perkus, J. Taylor, E. Norton, G. Allen, B. Languet, P. Desmettre, and E. Paoletti, J. Virol. 64, 2399-2406 (1990).
- 20 19. Guo, P., S. Goebel, S. Davis, M.E. Perkus, B. Languet, P. Desmettre, G. Allen, and E. Paoletti, J. Virol. 63, 4189-4198 (1989).
20. Kato, S. and K. Hirai, Adv. Virus Res. 30, 225-277 (1985).
25
21. Mandecki, W., Proc. Natl. Acad. Sci. USA 83, 7177-7181 (1986).
22. Maniatis, T., E.F. Fritsch, and J. Sambrook, Molecular Cloning, Cold Spring Harbor Laboratory, NY 545 pages (1982).
30
23. Maniatis, T., E.F. Fritsch, and J. Sambrook, Molecular Cloning, Cold Spring Harbor Laboratory, NY 545 pages (1986).
35
24. Marchioli, C.C., R.J. Yancey, E.A. Petrovskis, J.G. Timmins and L.E. Post, J. Virol. 61, 3977-3981 (1987).
40
25. Nazerian, K., E.A. Stephens, J.M. Sharma, L.F. Lee, M. Gaillitis and R.L. Witter, Avian Diseases 21, 69-76 (1977).
- 45 26. Okazaki, W., H.G. Purchase, B.R. Burmester, Avian Dis 14, 413-429 (1970).
27. Ono, K., M. Takashima, T. Ishikawa, M. Hayashi, I. Yoshida, T. Konobe, K. Ikuta, K. Nakajima, S. Ueda, S. Kato and K. Hirai, Avian Dis 29, 533-539 (1985).
50
28. Panicali, D., and E. Paoletti, Proc. Natl. Acad. Sci. USA 79, 4927-4931 (1982).

29. Paoletti, E., B.L. Lipinskas, C. Samsonoff, S. Mercer and D. Panicali, *Proc. Nat. Acad. Sci.* **81**, 193-197 (1984).
- 5 30. Payne, L.N., J.A. Frazier, P.C. Powell, *Int. Rev. Exp. Pathol.* **16**, 59-153 (1976).
31. Payne, L.N. *In* Marek's Disease, ed. L.N. Payne (Martinus Nijhoff, Boston) pp. 43-76 (1985).
- 10 32. Perkus, M.E., S.J. Goebel, S.W. Davis, G.P. Johnson, K. Limbach, E.K. Norton, and E. Paoletti, *Virology* **179**, 276-286 (1990).
- 15 33. Perkus, M.E., K. Limbach, and E. Paoletti, *J. Virol.* **63**, 3829-3836 (1989).
34. Perkus, M.E., A. Piccini, B.R. Lipinskas, and E. Paoletti, *Science* **229**, 981-984 (1985).
- 20 35. Piccini, A., M.E. Perkus, and E. Paoletti, *In* Methods in Enzymology, Vol. 153, eds. Wu, R., and Grossman, L., (Academic Press) pp. 545-563 (1987).
- 25 36. Ross, L.J.N., M. Sanderson, S.D. Scott, M.M. Binns, T. Doel and B. Milne, *J. Gen. Virol.* **70**, 1789-1804 (1989).
37. Ross, L.J.N. and M.M. Binns, *J. Gen. Virol.* **72**, 939-947 (1991).
- 30 38. Ross, L.J.N., M.M. Binns and J. Pastorek, *J. Gen. Virol.* **72**, 949-954 (1991).
- 35 39. Sanger, F., S. Nicklen, and A.R. Coulson, *Proc. Natl. Acad. Sci. USA* **74**, 5463-5467 (1977).
40. Schat, K.A., *Cancer Surveys* **6**, 1-37 (1987).
- 40 41. Shapira, S.K., J. Chou, F.V. Richaud, and M.J. Casadaban, *Gene* **25**, 71-82 (1983).
42. Tabor, S., and C.C. Richardson, *Proc. Natl. Acad. Sci. USA* **84**, 4767-4771 (1987).
- 45 43. Tartaglia, J., S. Pincus and E. Paoletti, *Crit. Revs. in Immunol.* **10**, 13-30 (1990).
44. Taylor, J., R. Weinberg, Y. Kawaoka, R.G. Webster, and E. Paoletti, *Vaccine* **6**, 504-508 (1988a).
- 50 45. Taylor, J., R. Weinberg, B. Languet, P. Desmettre, and E. Paoletti, *Vaccine* **6**, 497-503 (1988b).

46. Taylor, J., C. Edbauer, A. Rey-Senelongue, J.F. Bouquet, E. Norton, S. Goebel, P. Desmettre, and E. Paoletti, J. Virol. **64**, 1441-1450 (1990).
- 5 47. Taylor, J., S. Pincus, J. Tartaglia, C. Richardson, G. Alkhatib, D. Briedis, M. Appel, E. Norton, and E. Paoletti, J. Virol. **65**, 4263-4272 (1991).
- 10 48. Yuen, L., and B. Moss, Proc. Natl. Acad. Sci. USA **84**, 6417-6421 (1987).

The claims defining the invention are as follows:

1. A recombinant poxvirus, containing therein DNA from Marek's disease virus coding for Marek's disease virus glycoprotein gB or gD in a nonessential region of the poxvirus genome, wherein said poxvirus is selected from the group consisting of:

5 (i) a recombinant vaccinia virus wherein regions C7L-K1L, J2R, B13R+B14R, A56R, and IL4 have been deleted therefrom, and further comprising exogenous DNA from Marek's disease virus coding for Marek's disease virus glycoprotein gB or gD in a nonessential region of the vaccinia genome;

(ii) a recombinant vaccinia virus wherein the open reading frames for the
10 thymidine kinase gene, the hemorrhagic region, the A type inclusion body region, the hemagglutinin gene, the host range region, and the large subunit, ribonucleotide reductase have been deleted therefrom, and further comprising exogenous DNA from Marek's disease virus coding for Marek's disease virus glycoprotein gB or gD in a nonessential region of the vaccinia genome; and

15 (iii) a ~~recombinant~~ ^{recombinant} poxvirus having virus encoded genetic functions inactivated therein so that the virus has attenuated virulence; said poxvirus further comprising exogenous DNA from Marek's disease virus coding for Marek's disease virus glycoprotein gB or gD and is inserted by recombination in a nonessential region of the poxvirus genome; wherein said poxvirus is a fowlpox virus which as attenuated virulence
20 through approximately 50 serial passages in chicken embryonated eggs followed by 25 passages on chicken embryo fibroblast cells, then subjecting the virus to four successive plaque purifications, and obtaining a plaque isolate and further amplifying the isolate in primary chick embryo fibroblast cells.

2. A recombinant poxvirus as in claim 1 wherein said DNA codes for Marek's
25 disease virus glycoprotein gB.

3. A recombinant poxvirus as in claim 1 wherein said DNA codes for Marek's disease virus glycoprotein gD.

4. A recombinant poxvirus as in any one of claims 1-3, wherein the poxvirus is a vaccinia virus.

30 5. A recombinant poxvirus as in any one of claims 1-3, wherein the poxvirus is a fowlpox virus.

6. A vaccine comprising a carrier and a recombinant poxvirus as claimed in any one of claims 1 to 5.

7. The recombinant vaccinia virus of claim 1, wherein regions C7L-K1L, J2R,
35 B13R+B14R, A56R, and IL4 have been deleted therefrom, and further comprising exogenous DNA from Marek's disease virus coding for Marek's disease virus glycoprotein gD or gB in a nonessential region of the vaccinia genome.

8. The recombinant vaccinia virus of claim 1, wherein the open reading frames for the thymidine kinase gene, the hemorrhagic region, the A type inclusion body region,
40 the hemagglutinin gene, the host range region, and the large subunit, ribonucleotide



reductase have been deleted therefrom, and further comprising exogenous DNA from Marek's disease virus coding for a Marek's disease virus glycoprotein gB or gD in a nonessential region of the vaccinia genome.

9. The recombinant poxvirus of claim 1, having virus encoded genetic functions
5 inactivated therein so that the virus has attenuated virulence; said poxvirus further comprising exogenous DNA from Marek's disease virus coding for Marek's disease virus glycoprotein gB or gD and is inserted by recombination in a nonessential region of the poxvirus genome; wherein said poxvirus is a fowlpox virus which as attenuated virulence through approximately 50 serial passages in chicken embryonated eggs followed by 25
10 passages on chicken embryo fibroblast cells, then subjecting the virus to four successive plaque purifications, and obtaining a plaque isolate and further amplifying the isolate in primary chick embryo fibroblast cells.

10. A recombinant poxvirus comprising exogenous DNA from Marek's disease virus coding for Marek's disease virus glycoprotein gB or gD which is inserted by
15 recombination in a nonessential region of the poxvirus genome; wherein said poxvirus is a TROVAC recombinant fowlpox.

11. The recombinant poxvirus of claim 1, containing exogenous DNA for a promoter linked to the DNA from Marek's disease virus.

12. The recombinant poxvirus of claim 11, wherein the poxvirus is a fowlpox
20 virus.

13. The recombinant poxvirus of claim 11, wherein the poxvirus is a vaccinia virus.

14. An immunological composition for inducing an immunological response in a chicken inoculated with said composition, said composition comprising a carrier and a
25 recombinant poxvirus as claimed in claim 1.

15. An immunological composition comprising a carrier and a recombinant vaccinia virus as claimed in claim 7.

16. An immunological composition comprising a carrier and a recombinant vaccinia virus as claimed in claim 8.

30 17. An immunological composition comprising a carrier and a recombinant poxvirus as claimed in claim 9.

18. An immunological composition comprising a carrier and a recombinant poxvirus as claimed in claim 10.

19. A recombinant poxvirus containing therein DNA from Marek's disease virus
35 coding for Marek's disease virus glycoprotein gB or gD substantially as hereinbefore described with reference to any one of the Examples.

20. A vaccine comprising a carrier and a recombinant poxvirus as claimed in claim 19.





21. An immunological composition for inducing an immunological response in a chicken, said composition comprising a carrier and a recombinant poxvirus as claimed in claim 19.

Dated 11 November, 1996
Virogenetics Corporation


5

Patent Attorneys for the Applicant/Nominated Person
SPRUSON & FERGUSON




1/7

FIGURE 1




2/7

FIGURE 2




3/7

FIGURE 3




4/7

FIGURE 4



5/7

FIGURE 5



6/7

FIGURE 6





FIGURE 7



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US93/00084

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) : C12P 21/02, 19/34; C12N 15/00, 7/00, 5/00; A61K 39/12; C07K 3/00

US CL : 435/69.3, 91, 172.3, 235.1, 240.2; 424/89; 530/350

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/69.3, 91, 172.3, 235.1, 240.2; 424/89; 530/350

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE, BIOSIS, APS, search terms: poxvirus, Marek's disease virus, vaccinia virus, glycoprotein gB, glycoprotein gD

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 4,603,112 (Paoletti et al.) 29 July 1986, col. 1-3.	1-15
Y	Methods in Enzymology, Volume 153, issued 1987, Piccini, A. et al. "Vaccinia Virus as an Expression Vector", pages 545-563, see entire document.	1-15
Y	Vaccine, Volume 6, issued December, 1988, Taylor, J. et al., "Protective Immunity Against Avian Influenza Induced by a Fowlpox Virus Recombinant", pages 504-508, see entire document.	1-15

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A document defining the general state of the art which is not considered to be part of particular relevance	*X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E earlier document published on or after the international filing date	*Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z document member of the same patent family
*O documents referring to an oral disclosure, use, exhibition or other means	
*P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 25 March 1993	Date of mailing of the international search report 06 APR 1993
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. NOT APPLICABLE	Authorized officer JOAN ELLIS <i>Dyna Kyza for</i> Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US93/00084

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Vaccine, Volume 6, issued December 1988, Taylor, J. et al., "Recombinant Fowlpox Virus Inducing Protective Immunity in Non-Avian Species", pages 497-503, see entire document.	1-15
Y	Journal of Virology, Volume 64, No. 4, issued April, 1990, Taylor, J. et al., "Newcastle Disease Virus Fusion Protein Expressed in a Fowlpox Virus Recombinant Confers Protection in Chickens", pages 1441-1450, see entire document.	1-15
Y	Journal of Virology, Volume 65, No. 8, issued August, 1991, Taylor, J. et al., "Vaccinia Virus Recombinants Expressing Either the Measles Virus Fusion or Hemagglutinin Glycoprotein Protect Dogs Against Canine Distemper Virus Challenge", pages 4263-4274, see entire document.	1-15
Y	Journal of General Virology, Volume 70, issued September 1989, Ross, L.J.N. et al., "Nucleotide Sequence and Characterization of the Marek's Disease Virus Homologue of Glycoprotein B of Herpes Simplex Virus", pages 1789-1804, see entire document.	1-15
Y	Journal of General Virology, Volume 72, issued January 1991, Ross, L.J.N. et al., "Properties and Evolutionary Relationships of the Marek's Disease Virus Homologues of Protein Kinase, Glycoprotein D and Glycoprotein I of Herpes Simplex Virus", pages 939-947, see entire document.	1-15
Y	Journal of General Virology, Volume 72, issued January 1991, Ross, L.J.N. et al., "DNA Sequence and Organization of Genes in a 5.5 kbp <u>Eco</u> RI Fragment Mapping in the Short Unique Segment of Marek's Disease Virus (Strain RB1B)", pages 949-954, see entire document.	1-15